Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AbbVie : adds biologic production capability to Singapore facility

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 12:12pm CEST

The plant is the 13th site within the companys global manufacturing network which spans across the US, Europe and Puerto Rico, and is the only one of its kind within the network with the capability to produce both biologics and APIs. AbbVie employs around 400 workers in Singapore, around 250 of which serve at the manufacturing plant.

Singapores Minister for Trade and Industry, S Iswaran, was present at the opening ceremony, where he said the facility expansion came at an opportune moment to meet the increasing demands of ageing populations and technological advancement.

"While these shifts will disrupt existing business models, they also present significant new opportunities," he said.

According to Iswaran, the countrys government is committed to investing S$4 billion in health and biomedical sciences in addition to a further S$3.2 billion in advanced manufacturing and engineering as part of the Research Innovation and Enterprise (RIE) 2020 plan, a programme jointly developed by Workforce Singapore and the Singapore Economic Development Board.

"A strategic goal of RIE 2020 is to strengthen linkages between public research performers and private enterprises to create greater value from our investments in R&D," Iswaran noted.

Over 350 people have benefitted from the programme since its inception in 2014.

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
10/13 ABBVIE : obtains licence for Turnstone Biologics oncolytic viral immunotherapies
10/13 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET Data to be Presented at..
10/12 ABBVIE : and Turnstone Biologics Announce Global Collaboration on Viral Immunoth..
10/12 ABBVIE : ex-dividend day
10/11 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pib..
10/11 ABBVIE : ABBV), Turnstone Biologics Announce Pact on Viral Immunotherapies in On..
10/11 ABBVIE : Dividend Coverage: This Pharmaceutical Company has Raised Dividend By 6..
10/11 ABBVIE : to Host Third - Quarter 2017 Earnings Conference Call
10/11 ABBVIE : jumps on the oncolytics bandwagon, embracing Turnstone in new collabora..
10/10 ABBVIE : Collierville man awarded $140 million in lawsuit over testosterone drug..
More news
News from SeekingAlpha
08:39a FFF PORTFOLIO : Nam Tai Takes Off And Adding Qualcomm
10/16 BIOTECH FORUM DAILY DIGEST : Aratana Therapeutics Back In The Spotlight
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 TG Therapeutics down 20% premarket on potential extended timeline for U.S. ma..
10/13 ROCHE AND ALLERGAN : Approaches To Alzheimer's
Financials ($)
Sales 2017 27 965 M
EBIT 2017 11 934 M
Net income 2017 7 394 M
Debt 2017 25 874 M
Yield 2017 2,85%
P/E ratio 2017 19,53
P/E ratio 2018 15,75
EV / Sales 2017 6,11x
EV / Sales 2018 5,41x
Capitalization 145 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 92,7 $
Spread / Average Target 1,8%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE44.79%145 126
MERCK KGAA-2.27%14 740
KYOWA HAKKO KIRIN CO LTD23.05%10 229
JAZZ PHARMACEUTICALS PLC29.67%8 439
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD29.42%5 622
CONVATEC GROUP19.41%5 314